-+ 0.00%
-+ 0.00%
-+ 0.00%

Hanyu Pharmaceutical (300199.SZ): Liraglutide API was accepted by Korea's MFDS

Zhitongcaijing·05/06/2025 13:33:07
Listen to the news

Zhitong Finance App News, Hanyu Pharmaceutical (300199.SZ) issued an announcement. Recently, the Liraglutide API from Hanyu Pharmaceutical (Wuhan) Co., Ltd., a wholly-owned subsidiary of the company, was approved and accepted by the Korea Food and Drug Administration (hereinafter referred to as “MFDS”).

According to reports, liraglutide is an analogue of human glucagon-like peptide-1 (GLP-1). The GLP-1 receptor is an important drug target and has various physiological functions: blood sugar dependency promotes insulin secretion, protects pancreatic beta cells, and delays gastric emptying to reduce appetite.